美國居民不適用 XM 服務。

B
B

BayerAG

財經新聞

Reuters - 4天前

Water finance pipe is full of recycled pledges

BREAKINGVIEWS-Water finance pipe is full of recycled pledges The author is a Reuters Breakingviews columnist. The opinions expressed are his own. Refiles to change dateline. By Antony Currie NEW YORK, March 28 (Reuters Breakingviews) - Few enjoy being packed like sardines in a windowless conference room in the bowels of the United Nations. But for the financially-straitened water industry, the prospect of being inundated with cash was more than enough.
A
A
B
V
A
C
S
X
Reuters - 1週前

Bayer's pharma chief hopes EU takes time to improve drug rules reform

UPDATE 1-Bayer's pharma chief hopes EU takes time to improve drug rules reform Shorter drug exclusivity 'catastrophic' -Bayer executive Oelrich Oelrich says U.S. market more attractive than Europe Warns that IRA rules could lead to fewer drug use cases Adds comment on new U.S. drug pricing rules By Ludwig Burger and Patricia Weiss FRANKFURT, March 24 (Reuters) - The European Union's decision to postpone rule changes for the pharmaceutical industry could open the way for a rethink of a decision t
B
Reuters - 1週前

Bayer exec says he hopes EU takes time to improve drug rules reform

Bayer exec says he hopes EU takes time to improve drug rules reform By Ludwig Burger and Patricia Weiss FRANKFURT, March 24 (Reuters) - The head of Bayer's BAYGn.DE pharmaceuticals unit said he hopes a recent European Union decision to postpone rule changes for the pharmaceutical industry means that a cut in intellectual drug property protection will be reconsidered.
B
Reuters - 1週前

Bayer says drug research focus no longer on women's health

UPDATE 1-Bayer says drug research focus no longer on women's health adds detail By Ludwig Burger and Patricia Weiss FRANKFURT, March 24 (Reuters) - Bayer BAYGn.DE said the focus of its drug research would shift away from women's health, a traditional pillar of Germany's largest drugmaker, to hone in on neurology, rare diseases and immunology. "When it comes to research and the subsequent clinical phases, we will no longer have an explicit focus on women's health," the head of Bayer's pharmaceuti
B
Reuters - 1週前

Bayer says drug research focus no longer on women's health

Bayer says drug research focus no longer on women's health By Ludwig Burger and Patricia Weiss FRANKFURT, March 24 (Reuters) - Bayer BAYGn.DE said the focus of its drug research would shift away from women's health, a traditional pillar of Germany's largest drugmaker, to hone in on neurology, rare diseases and immunology. "When it comes to research and the subsequent clinical phases, we will no longer have an explicit focus on women's health," the head of Bayer's pharmaceuticals unit, Stefan Oel
B
Reuters - 1週前

GSK loses bid to keep experts out of upcoming Zantac trial

UPDATE 3-GSK loses bid to keep experts out of upcoming Zantac trial New throughout; adds comment from plaintiffs, background By Maggie Fick and Brendan Pierson March 24 (Reuters) - A California judge on Thursday denied GSK Plc's GSK.L bid to keep expert testimony linking its discontinued heartburn drug Zantac to cancer out of an upcoming trial, a setback for the British drugmaker facing lawsuits over the medicine in courts across the United States.
B
G
P
S
Reuters - 1週前

Bayer Expands Global Clinical Program For Nubeqa® (Darolutamide) In Prostate Cancer

BRIEF-Bayer Expands Global Clinical Program For Nubeqa® (Darolutamide) In Prostate Cancer March 23 (Reuters) - Bayer AG BAYGn.DE : BAYER EXPANDS GLOBAL CLINICAL PROGRAM FOR NUBEQA® (DAROLUTAMIDE) IN PROSTATE CANCER Source text for Eikon: ID:nBwbf3WPba Further company coverage: [BAYGn.DE]
B
Reuters - 1週前

Bayer Expands Global Clinical Program For Darolutamide In Prostate Cancer

BRIEF-Bayer Expands Global Clinical Program For Darolutamide In Prostate Cancer March 23 (Reuters) - Bayer AG BAYGn.DE : BAYER EXPANDS GLOBAL CLINICAL PROGRAM FOR DAROLUTAMIDE IN PROSTATE CANCER Source text for Eikon: [ID:] Further company coverage: [BAYGn.DE]
B
Reuters - 1週前

Syngenta’s weakening crops may dim IPO prospects

BREAKINGVIEWS-Syngenta’s weakening crops may dim IPO prospects The author is a Reuters Breakingviews columnist. The opinions expressed are their own. LONDON, March 22 (Reuters Breakingviews) - Syngenta’s earnings hit comes at an unfortunate time. The Chinese-owned pesticides-to-seeds maker, once listed in Zurich, is preparing a stock market comeback in Shanghai this year, hoping to fetch a valuation as high as $60 billion.
B
B
C
C
Reuters - 1週前

Syngenta's $9.5 bln IPO moves closer with Shanghai bourse hearing

UPDATE 3-Syngenta's $9.5 bln IPO moves closer with Shanghai bourse hearing Shanghai bourse to review IPO filing on March 29 Syngenta plans to raise around $9.5 billion Flotation expected to be launched in June -sources Adds detail, data, context By John Revill and Julie Zhu ZURICH/HONG KONG, March 22 (Reuters) - Syngenta's $9.5 billion flotation has moved a step closer after the Shanghai Stock Exchange scheduled a hearing next week for the Swiss agrichemicals and seeds company's listing plan .
B
B
C
Reuters - 1週前

Syngenta 4Q profit falls as raw material prices increase

Syngenta 4Q profit falls as raw material prices increase ZURICH, March 22 (Reuters) - Swiss agrichemicals and seeds group Syngenta on Wednesday reported a 25% drop in fourth quarter earnings due to higher raw materials and energy costs. Syngenta, which plans to list within the next few months, also spent more on reorganising its business and set cash aside to cover macro-economic uncertainties such as further raw material spikes or potential bad debts by customers.
B
B
C
Reuters - 2週前

Pressure rises on Bayer chair as DWS criticises excess board seats

Pressure rises on Bayer chair as DWS criticises excess board seats By Ludwig Burger and Patricia Weiss FRANKFURT, March 20 (Reuters) - Asset manager DWS DWSG.DE on Monday joined in criticism of the multiple board commitments of Bayer's BAYGn.DE chairman, adding to upheaval at the drugmaker, which is the target of activist investors in the run-up to a change of CEO on June 1. Hendrik Schmidt, a corporate governance expert at Germany's DWS, told Reuters that his questions at Bayer's annual shareho
B
D
R
Reuters - 2週前

Orion's Darolutamide Approved For Additional Prostate Cancer Indication In China

BRIEF-Orion's Darolutamide Approved For Additional Prostate Cancer Indication In China March 20 (Reuters) - Orion Oyj ORNBV.HE : DAROLUTAMIDE APPROVED FOR ADDITIONAL PROSTATE CANCER INDICATION IN CHINA DAROLUTAMIDE IS ALREADY APPROVED IN CHINA FOR TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER APPROVAL IS BASED ON POSITIVE RESULTS FROM PHASE III ARASENS TRIAL DAROLUTAMIDE IS DEVELOPED JOINTLY BY ORION AND BAYER.
B
Reuters - 2週前

Bayer Says Nubeqa (Darolutamide) Approved For Additional Prostate Cancer Indication In China

BRIEF-Bayer Says Nubeqa (Darolutamide) Approved For Additional Prostate Cancer Indication In China March 20 (Reuters) - Bayer AG BAYGn.DE : BAYER AG - NUBEQA™ (DAROLUTAMIDE) APPROVED FOR ADDITIONAL PROSTATE CANCER INDICATION IN CHINA Source text for Eikon: [ID:] Further company coverage: [BAYGn.DE] (Gdansk Newsroom)
B
Reuters - 3週前

Bayer Says Subsidiary To Collaborate With Rune Labs And Emerald Innovations

BRIEF-Bayer Says Subsidiary To Collaborate With Rune Labs And Emerald Innovations March 14 (Reuters) - Bayer AG BAYGn.DE : BLUEROCK THERAPEUTICS LP, A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY AND WHOLLY-OWNED, INDEPENDENTLY OPERATED SUBSIDIARY OF BAYER AG, TODAY ANNOUNCED A COLLABORATION WITH RUNE LABS AND EMERALD INNOVATIONS RESULTS FROM THE PHASE
B
Reuters - 3週前

Union Investment won't back new term for Bayer supervisory board chairman - WiWO

Union Investment won't back new term for Bayer supervisory board chairman - WiWO BERLIN, March 10 (Reuters) - Bayer BAYGn.DE shareholder Union Investment will not back the re-election of the drugmaker's supervisory board chair, fund manager Janne Werning said in comments to the WirtschaftsWoche business news outlet published on Friday. "We will vote against the re-election of Mr.
B
Reuters - 3週前

Bayer plans to spend $1 bln on US pharma R&D in 2023-US pharma head

Bayer plans to spend $1 bln on US pharma R&D in 2023-US pharma head By Michael Erman and Patrick Wingrove NEW YORK, March 9 (Reuters) - Bayer AG BAYGn.DE plans to spend $1 billion on drug research and development in the U.S. this year as it works to double its sales in the country by the end of the decade, Bayer's top U.S. pharmaceutical executive told Reuters.
B
Reuters - 3週前

What is the Mexico GM corn dispute about?

EXPLAINER-What is the US-Mexico GM corn dispute about? By Cassandra Garrison March 8 (Reuters) - The U.S. has requested formal trade consultations with Mexico over the Latin American country's plans to restrict imports of genetically modified corn. The North American neighbors will inch closer to a full-blown trade dispute under the U.S.-Mexico-Canada Agreement on trade (USMCA) if there is no resolution during the talks, which Mexico says will last one month.
B
C
Reuters - 3週前

Brenntag bets on resilient 2023, raises dividend

UPDATE 3-Germany's Brenntag predicts resilient 2023, reiterates plan to double M&A spend Earnings, outlook in line with analysts forecasts Brenntag to pay higher dividend for 2022 Share buyback programme of up to 6.8% of stock Reiterates doubling of M&A budget Adds CEO, background, updates shares By Tristan Chabba and Bartosz Dabrowski March 8 (Reuters) - German chemicals distributor Brenntag BNRGn.DE forecast resilient earnings on Wednesday and reiterated plans to double its mergers and acquisi
B
B
T
Reuters - 4週前

Bayer: New Organ-On-Chip Pilot Seeks To Reduce Animal Testing In Consumer Health Industry

BRIEF-Bayer: New Organ-On-Chip Pilot Seeks To Reduce Animal Testing In Consumer Health Industry March 7 (Reuters) - Bayer AG BAYGn.DE : NEW ORGAN-ON-CHIP PILOT SEEKS TO REDUCE ANIMAL TESTING IN CONSUMER HEALTH INDUSTRY ONE-YEAR PILOT WILL FOCUS ON EVALUATING WHETHER SMALL MOLECULES CAN CROSS BLOOD-PLACENTA-BARRIER IN PREGNANT WOMEN Source text for
B

細節

熱門資產

免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。

我們運用 cookies 提供您最佳之網頁使用經驗。更改您的cookie 設定跟詳情。

風險提示：您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明。